Showing results (321-330 of 470) with videos related to

Sort By:
Pageof 47
Journal of the National Cancer Institute|September 10, 2021
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer TrialsJun Yin, Mohamed E Salem, Jesse G Dixon, et al.
The Lancet. Oncology|October 17, 2016
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) databaseJan Franko, Qian Shi, Jeffrey P Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal CancerJeremy C Jones, Lindsay A Renfro, Humaid O Al-Shamsi, et al.
The Lancet. Oncology|May 7, 2021
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trialSalvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, et al.
Clinical Pharmacology and Therapeutics|February 1, 2018
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen TherapyMatthew P Goetz, Katrin Sangkuhl, Henk-Jan Guchelaar, et al.
JCO Precision Oncology|October 5, 2020
Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA AssayKatherine Clifton, Thereasa A Rich, Christine Parseghian, et al.
The New England Journal of Medicine|March 29, 2018
Duration of Adjuvant Chemotherapy for Stage III Colon CancerAxel Grothey, Alberto F Sobrero, Anthony F Shields, et al.
JAMA|April 6, 2021
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical TrialJeffrey A Meyerhardt, Qian Shi, Charles S Fuchs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2020
Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal CancerJim P Abraham, Daniel Magee, Chiara Cremolini, et al.
Future Oncology (London, England)|October 12, 2021
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancerCiara C O'Sullivan, Karla V Ballman, Linda McCall, et al.
Pageof 47